Answer
It is unknown whether tigecycline or its metabolites pass into human breast milk; infant risk cannot be excluded, so a decision to discontinue breastfeeding or discontinue or avoid tigecycline must weigh breastfeeding benefits for the child against treatment benefits for the woman.
Sources for this answer
- Tygacil 50mg powder for solution for infusion / Tigecycline 50 mg powder for solution for infusionPfizer Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 42Document updated
Sources checked